Metformin for longevity evidence dosing debate and access

Metformin sits in an unusual spot: it is one of the most-prescribed, best-understood drugs in the world, yet its longevity reputation rests on softer ground than most people assume. This page lays out where the case is strong, where it is thin, and the one real downside that gets glossed over.

Why metformin became a longevity candidate

The interest started with epidemiology — observations that people with diabetes taking metformin sometimes did better on certain outcomes than expected. That signal is the basis for the widely discussed rationale to test metformin as an anti-aging intervention, formalised in the proposal for the TAME trial.^[1] The idea is appealing and the biology is plausible, but note what it is: a rationale for a trial, not the result of one.

Strong rationale · outcome unproven

The exercise trade-off you should know about

Here is the honest complication. A randomised study in older adults found that metformin reduced some of the mitochondrial adaptations to aerobic exercise training — in other words, it may partly interfere with the benefits of the single most evidence-backed longevity behaviour there is.^[2] If structured training is central to how you invest in your health, this is a real tension, not a footnote.

The evidence gap for healthy people

Most of the useful metformin data comes from people who have diabetes or are at high metabolic risk. Extending those findings to metabolically healthy adults is an assumption, not a demonstration. Until a trial like TAME actually reports, "metformin for longevity in healthy people" should be filed under promising-but-unproven — the kind of distinction we try to keep clear across our longevity evidence desk. It is a very different level of certainty from, say, exercise or not smoking.

The dosing debate

Metformin's dosing is well established for diabetes, but there is no settled "longevity dose or schedule," and no reliable way to confirm you are getting an anti-aging effect rather than simply a glucose-lowering one. Anyone treating a specific longevity protocol as fact is getting ahead of the evidence. If you are comparing mechanisms, our side-by-side of rapamycin and metformin lays out how differently the two drugs act.

How people access it — legitimately

Metformin is prescription-only. The appropriate routes are a licensed physician who will discuss it and monitor you, or a regulated telehealth clinic that includes a genuine consultation. We do not sell metformin and we do not point to grey-market or no-prescription sources. If a site offers it with "no prescription needed," treat that as a red flag. For the drug with the deeper mouse-lifespan record, see our main rapamycin guide.

Go deeper

• Rapamycin for longevity: what the evidence shows
• Rapamycin vs metformin, compared

Frequently asked questions

Does metformin extend lifespan in healthy people?

This has not been proven. The longevity interest comes from diabetes epidemiology and the rationale for the TAME trial, but there is no completed trial showing metformin extends life or healthspan in people without diabetes.

Can metformin blunt exercise gains?

There is real evidence it can. A randomised study in older adults found metformin reduced some of the mitochondrial adaptations to aerobic exercise training. If regular training is central to your health plan, this trade-off is worth discussing with a clinician.

Can I buy metformin without a prescription for longevity?

No. Metformin is a prescription-only medication. The legitimate routes are a licensed physician or a regulated telehealth service that includes a real consultation. We do not sell it or point to no-prescription sources.

What is the TAME trial?

TAME (Targeting Aging with Metformin) is a proposed large trial designed to test whether metformin delays age-related diseases as a group. Its rationale is why metformin is discussed for longevity, but the outcome data that would settle the question does not exist yet.

Is metformin the same as rapamycin?

No. They are different drugs acting through different pathways. Rapamycin inhibits mTOR and has strong mouse lifespan data; metformin's longevity case rests mainly on human epidemiology in people with diabetes. Both are prescription-only and unproven for lifespan in healthy people.